Ariclaim

RSS

duloxetine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Ariclaim has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 07/08/2018

Authorisation details

Product details
Name
Ariclaim
Agency product number
EMEA/H/C/000552
Active substance
duloxetine
International non-proprietary name (INN) or common name
duloxetine
Therapeutic area (MeSH)
Diabetic Neuropathies
Anatomical therapeutic chemical (ATC) code
N06AX21
Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Revision
26
Date of issue of marketing authorisation valid throughout the European Union
11/08/2004
Contact address

Papendorpseweg 83
3528 BJ Utrecht
Netherlands

Product information

09/12/2016 Ariclaim - EMEA/H/C/000552 - N/0066

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Psychoanaleptics

Therapeutic indication

Treatment of diabetic peripheral neuropathic pain.

Ariclaim is indicated in adults.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating